Fulcrum Therapeutics Hands the Keys to Slate Medicines in $350M All-Stock Merger, SLTE to Trade on Nasdaq

Fulcrum Therapeutics (Nasdaq: FULC) announced on August 17, 2026, that it will merge with privately held Slate Medicines in an all-stock transaction — a deal that values Slate at $350 million and Fulcrum at $31.3 million, according to the companies' joint press release on GlobeNewswire.

The ownership split tells the story plainly: pre-merger Fulcrum stockholders are expected to own 5.0% of the combined company, while pre-merger Slate stockholders — including investors in the pre-closing financing — are expected to own 95.0%. Fulcrum is expected to contribute approximately $20.3 million in net cash to the combined entity and pay a cash dividend of an estimated $270.0 million immediately prior to close to its own stockholders. For Fulcrum's existing shareholders, that dividend is the headline number.

The circumstances that produced this deal are specific. Per BioPharma Dive's coverage, Fulcrum discontinued development of pociredir — its lead sickle cell drug — after the FDA flagged potential cancer risks, triggering an 85% workforce reduction that left the company with nine employees. With its pipeline gone and its headcount cut to single digits, Fulcrum's chief remaining asset was its cash. The deal converts that cash into a stake in Slate's migraine-focused programs and hands operational control entirely to Slate CEO Gregory Oakes, who will lead the combined company.

Slate comes with a clinical-stage program. SLTE-1009 is a subcutaneous anti-PACAP/VIP monoclonal antibody for the prevention of migraine and other headache disorders, per the August 17 press release. The company is also developing SLTE-2100, a bispecific antibody targeting PACAP/VIP and CGRP, which is expected to enter clinical trials in the second half of 2027.

Fueling the combined entity is a $245 million private placement that was oversubscribed, according to the press release. The syndicate is led by Frazier Life Sciences and includes Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments, and Mingxin Capital. The raise is anticipated to fund operations into 2029.

Upon closing, the company will operate as Slate Medicines, Inc. and trade on Nasdaq under the ticker symbol SLTE. The transaction is expected to close in the fourth quarter of 2026, subject to stockholder approval and other customary conditions, per the SEC Form 8-K filed August 17, 2026.

This deal lands inside a broader consolidation wave. The August 17 press release and BioPharma Dive both note recent transactions including Merck's acquisition of Terns Pharmaceuticals, Novartis' purchase of Avidity Biosciences, Eli Lilly's acquisitions of Ajax Therapeutics and Kelonia Therapeutics, and Gilead Sciences' oncology-focused acquisitions of Arcellx and Tubulis — all illustrating how large players are buying innovation rather than building it. SLTE-1009's dual PACAP/VIP mechanism and the SLTE-2100 bispecific program targeting both PACAP/VIP and CGRP represent the scientific rationale Slate has put forward for the combined entity, per the August 17 press release.

The immediate next milestones are stockholder approval and Q4 2026 close, followed by the anticipated Nasdaq debut under SLTE and, further out, SLTE-2100's expected entry into clinical trials in the second half of 2027.